Replimune Q1 net loss narrows as expenses decline

Replimune

14/08/2026 13:14

Overview
US oncolytic immunotherapy firm's fiscal Q1 net loss narrowed year-over-year
Company received FDA accelerated approval for TUDRIQEV in advanced cutaneous melanoma
Company completed $150 mln financing to support commercial launch and confirmatory trial

Outlook
Company expects to launch TUDRIQEV in the U.S. within 60 days
Replimune says current cash and recent financing will fund operations for over 12 months
Company is actively enrolling patients in IGNYTE-3 confirmatory Phase 3 trial for TUDRIQEV

Result Drivers
FDA APPROVAL - Accelerated approval of TUDRIQEV in combination with nivolumab for advanced cutaneous melanoma cited as a key milestone
COST MANAGEMENT - Lower R&D and SG&A expenses due to reduced personnel and direct research costs

Company press release: ID:nGNX4b8z5d

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Loss Per Share
 
$0.72
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Replimune Group, Inc. is $16.50, about 8.6% above its August 13 closing price of $15.19

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)